DSMB completed the 2nd safety data review of 60 patients, of whom 59 completed the Day 4 evaluation. There were no SAEs, deaths, life-threatening AEs, or hospitalization because of adverse events. After reviewing the data, DSMB recommended study may continue without modification.
